Accelerate Diagnostics Performance
| AXDXDelisted Stock | USD 0.04 0.02 164.90% |
The firm shows a Beta (market volatility) of 0.4, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Accelerate Diagnostics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Accelerate Diagnostics is expected to be smaller as well. At this point, Accelerate Diagnostics has a negative expected return of -8.96%. Please make sure to confirm Accelerate Diagnostics' total risk alpha, as well as the relationship between the kurtosis and market facilitation index , to decide if Accelerate Diagnostics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Accelerate Diagnostics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in August 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 12.1 M |
Accelerate |
Accelerate Diagnostics Relative Risk vs. Return Landscape
If you would invest 57.00 in Accelerate Diagnostics on April 22, 2025 and sell it today you would lose (53.00) from holding Accelerate Diagnostics or give up 92.98% of portfolio value over 90 days. Accelerate Diagnostics is currently does not generate positive expected returns and assumes 22.4214% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Accelerate, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Accelerate Diagnostics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Accelerate Diagnostics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Accelerate Diagnostics, and traders can use it to determine the average amount a Accelerate Diagnostics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.3995
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AXDX |
Estimated Market Risk
| 22.42 actual daily | 96 96% of assets are less volatile |
Expected Return
| -8.96 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.4 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Accelerate Diagnostics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Accelerate Diagnostics by adding Accelerate Diagnostics to a well-diversified portfolio.
Accelerate Diagnostics Fundamentals Growth
Accelerate Stock prices reflect investors' perceptions of the future prospects and financial health of Accelerate Diagnostics, and Accelerate Diagnostics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Accelerate Stock performance.
| Return On Asset | -0.74 | |||
| Operating Margin | (2.82) % | |||
| Current Valuation | 50.42 M | |||
| Shares Outstanding | 25.29 M | |||
| Price To Earning | (15.18) X | |||
| Price To Sales | 0.07 X | |||
| Revenue | 11.7 M | |||
| EBITDA | (33.57 M) | |||
| Cash And Equivalents | 36.77 M | |||
| Cash Per Share | 0.45 X | |||
| Total Debt | 66.58 M | |||
| Debt To Equity | 2.76 % | |||
| Book Value Per Share | (2.23) X | |||
| Cash Flow From Operations | (24.19 M) | |||
| Earnings Per Share | (2.15) X | |||
| Total Asset | 28.56 M | |||
| Retained Earnings | (718.9 M) | |||
| Current Asset | 91.68 M | |||
| Current Liabilities | 4.45 M | |||
About Accelerate Diagnostics Performance
Evaluating Accelerate Diagnostics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Accelerate Diagnostics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Accelerate Diagnostics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona. Accelerate Diagnosti operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 220 people.Things to note about Accelerate Diagnostics performance evaluation
Checking the ongoing alerts about Accelerate Diagnostics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Accelerate Diagnostics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Accelerate Diagnostics is not yet fully synchronised with the market data | |
| Accelerate Diagnostics generated a negative expected return over the last 90 days | |
| Accelerate Diagnostics has high historical volatility and very poor performance | |
| Accelerate Diagnostics has some characteristics of a very speculative penny stock | |
| Accelerate Diagnostics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 11.7 M. Net Loss for the year was (50.05 M) with profit before overhead, payroll, taxes, and interest of 2.7 M. | |
| Accelerate Diagnostics currently holds about 36.77 M in cash with (24.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 38.0% of the company shares are held by company insiders |
- Analyzing Accelerate Diagnostics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Accelerate Diagnostics' stock is overvalued or undervalued compared to its peers.
- Examining Accelerate Diagnostics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Accelerate Diagnostics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Accelerate Diagnostics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Accelerate Diagnostics' stock. These opinions can provide insight into Accelerate Diagnostics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Other Consideration for investing in Accelerate Stock
If you are still planning to invest in Accelerate Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Accelerate Diagnostics' history and understand the potential risks before investing.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |